1492 Capital Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

1492 Capital Management’s Portfolio KERX Stock Details KERX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-264,297	Closed	-$2.64M	–	140
2015 Q2	$2.64M	Sell	264,297 -14,588	-5%	-$156K	1.67%	24
2015 Q1	$3.55M	Buy	278,885 +226,127	+429%	+$2.91M	2.06%	17
2014 Q4	$747K	Sell	52,758 -3,434	-6%	-$53.2K	0.47%	63
2014 Q3	$773K	Buy	56,192 +26,483	+89%	+$405K	0.43%	56
2014 Q2	$457K	Sell	29,709 -792	-3%	-$11.2K	0.23%	82
2014 Q1	$520K	Buy	+30,501	New	+$460K	0.26%	90

Other funds holding KERX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

ACM

Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return

1492 Capital Management's KERX Position: Q3 2015 in Review

1492 Capital Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q3 2015, closing a stake of 264,297 shares — an estimated $2.64M sold.

1492 Capital Management first reported a position in KERX in Q1 2014 and held it in 6 quarters. The position peaked at $3.55M in Q1 2015. 138 funds tracked by Wall St. Rank hold KERX as of Q3 2015.

1492 Capital Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q3 2015 after selling out during the quarter.
1492 Capital Management sold 264,297 Keryx Biopharmaceuticals Inc shares in Q3 2015, an estimated $2.64M.
1492 Capital Management first reported a position in Keryx Biopharmaceuticals Inc in Q1 2014 and held it in 6 quarters.
1492 Capital Management's Keryx Biopharmaceuticals Inc position peaked at $3.55M in Q1 2015.
138 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q3 2015.

Based on 1492 Capital Management's 13F filing for Q3 2015, filed 13 Nov 2015.